Search for a trial

A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined with Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants with Non-Small Cell Lung Cancer (NSCLC)

Sub-study APhase 1b:To assess the DLT rate and estimate the MTD of sasanlimab in combination with encorafenib and binimetinib to determine the RP2D for the combination. Phase 2:To assess the durable ORR of sasanlimab in combination with encorafenib…

Injection of 99mTc-nanocolloid and ICG to identify, retrieve and qualify tumor draining lymph nodes in early-stage lungcancer

The primary objective is to determine the feasibility of identifying the TDLN in patients with NSCLC (cT1 to cT2b) on SPECT/CT imaging and during surgical resection using a radioactive and fluorescent tracer, 99mTc-nanocolloïd and ICG respectively.…

Laparoscopic laser speckle contrast imaging for the demarcation of lung segments

In this trial we will study the utility of PerfusiX-Imaging for the identification of intersegmental planes during thoracoscopic segmentectomy.

A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants with Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non Small Cell Lung Cancer

This study has been transitioned to CTIS with ID 2023-505057-40-00 check the CTIS register for the current data. This study is looking at how safe the combination of the experimental drugs dostarlimab, belrestotug and GSK6097608 is in patients with…

A randomized, double-blind, international multicenter, phase III study to evaluate the anti-tumor efficacy and safety of HLX10 (recombinant humanized anti-PD-1 monoclonal antibody injection) or placebo in combination with chemotherapy (carboplatin/cisplatin-etoposide) and concurrent radiotherapy in patients with limited-stage small cell lung cancer (LS-SCLC)

This study has been transitioned to CTIS with ID 2024-515047-31-00 check the CTIS register for the current data. Primary objective:- To evaluate the anti-tumor efficacy of HLX10 in combination with chemotherapy and concurrent radiotherapy in…

A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor

This study has been transitioned to CTIS with ID 2024-513770-22-00 check the CTIS register for the current data. Primary objective:• Evaluate the anti-tumor activity of GEN1046 as monotherapy and in combination with pembrolizumab in subjects with…

A clinical imaging Study of the changes in [18F]F-AraG uptake following radiotherapy in Non-small cell lung cancer.

This study has been transitioned to CTIS with ID 2024-517960-45-00 check the CTIS register for the current data. • To assess the relative change in uptake of [18F]F-AraG in tumor lesions upon anti-PD-1 treatment• To assess the relationships between…

A Phase 1/2, open-label, multicenter, dose escalation and dose expansion study of SAR442720 in combination with other agents in participants with advanced malignancies

The primary goal of Part 3 of this study is to evaluate the safety, recommended phase 2 dose (RP2D), antitumor effect and PK of SAR442720 in combination with KRAS G12C inhibitor adagrasib, in participants with NSCLC with KRAS G12C mutationsPart-3a…

KontRASt-06: An open-label phase II trial evaluating the activity and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression >= 1% and an STK11 co-mutation.

This study has been transitioned to CTIS with ID 2024-511708-18-00 check the CTIS register for the current data. the Sponsor aims to investigate if JDQ443 will stop abnormal cell growth related to the marker KRAS G12C mutation in patients with NSCLC…

A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations

This study has been transitioned to CTIS with ID 2023-509825-38-00 check the CTIS register for the current data. To compare the effect of ZIM and DOM in combination with chemotherapy relative to PEMBRO in combination with chemotherapy (Group A…

Upfront resection of locally-advanced or cavitating NSCLC followed by chemoradiotherapy (and adjuvant systemic treatment); Phase 1 multicenter study to assess treatment feasibility and safety

The primary aim of the UPLAN-I trial is to evaluate feasibility and safety of upfront resection of large volume or cavitating tumors in the lung (including a hilar and/or mediastinal lymph node dissection if deemed possible by the treating surgeon…

A Phase IIB, Open Label, Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET-CT in Subjects with Selected Advanced or Metastatic Malignancies including Melanoma, Merkel Cell, Renal Cell and Non-Small Cell Lung Cancers, Scheduled to Receive Standard-of-Care Immunotherapy (IOT) as a Single Agent or Combination, to Predict Response to Therapy

Primary objective: evaluate the performance of zirconium Zr 89 crefmirlimab berdoxam PET-CT for predicting patient response to immunotherapy. Secondary objectives: - evaluate the performance of zirconium Zr 89 crefmirlimab berdoxam PET-CT for…

Randomized phase III trial investigating the survival benefit of adding thoracic radiotherapy to durvalumab (MEDI4736) immunotherapy plus chemotherapy in extensive stage small-cell lung cancer

This study has been transitioned to CTIS with ID 2023-505514-15-00 check the CTIS register for the current data. Primary Objective:- To investigate whether adding TRT to durvalumab plus chemotherapy improves 1-year survival. Secondary Objectives:-…

A Phase 1b Study Evaluating the Safety and Efficacy of First-Line Tarlatamab in Combination
With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects with Extensive Stage Small Cell Lung
Cancer

This study has been transitioned to CTIS with ID 2024-511021-58-00 check the CTIS register for the current data. Primary Objective:- Number of participants with dose limiting toxicity - Number of participants with treatment-related adverse events -…